Collective IP Analysis | BioMarin Acquisition of Prosensa


On November 24th rare disease drug maker BioMarin Pharmaceuticals¬†announced it was buying Prosensa¬†for $840MM plus approval milestones. Prosensa has no marketed products but is in the late stages of obtaining approval for its lead drug candidate, drisapersen, for a rare form of muscular dystrophy. BioMarin will pay Prosensa shareholders an additional $80MM if drisapersen receives… Read more »

Incubating Hard Science Startups for Critical Human Needs


Peter Thiel’s Breakout Labs Shows A New Way Forward The traditional seed funding model rule-of-thumb, at least according to legendary tech investor Fred Wilson, is about discovering *product market fit*. “The first step is building a product, getting it into the market, and finding product market fit. I think that’s what seed financing should be… Read more »